Finally, a Reasonable Price For This Healthcare Blue Chip

The investor community holds high regard for healthcare conglomerate Abbott Laboratories (NYSE: ABT). Shares rarely come cheap, typically commanding a higher valuation than the S&P 500.

However today Abbott Labs is trading nearly 30% below its high, thanks to recent volatility on Wall Street.

The stock has crushed the market over the past five years, and the current dip may give investors a chance to do it again over the next five. Here is why Abbott Labs is a fantastic buy today.

COVID-19 carrying growth in the near term

Abbott Labs is a healthcare company that designs and sells various products, including consumer products, generic drugs, medical devices, lab equipment, and supplies. The business generated more than $44 billion in revenue over the past four quarters.

Abbott’s revenue has grown by an average of 15% annually over the past five years, while earnings-per-share (EPS) has averaged 33%. The company has a significant presence in diabetes, where its non-invasive glucose monitoring product, the FreeStyle Libre, grew sales 20% year over year in the first quarter of 2022 to $1 billion. It also has a substantial medical device segment, selling a range of cardiovascular products like pacemakers and pumps.

The company built a device that can rapidly diagnose COVID-19, which has helped carry growth throughout the pandemic. Its rapid test system made $3.5 billion worldwide in Q1 2022, a 57% increase over the prior year. Abbott’s total revenue grew by 13.8% year over year in Q1; COVID-19 rapid test sales could eventually fade, but Abbott’s a diverse company that grows in many ways.

A profitable business giving cash to investors

Healthcare has changed so much over time, so Abbott’s dividend track record might best speak for its long-term success. The company is a Dividend King with 50 consecutive years of dividend increases.

That means passive income for investors; the stock’s dividend yield is currently 1.8%, which likely beats putting money into a savings account. You can see below how steadily Abbott has grown over these decades, except for a massive spin-off in 2013 to form AbbVie from its pharmaceutical segment.

ABT Revenue (TTM) data by YCharts.

Abbott is very profitable, turning about $0.20 of each revenue dollar into free cash flow, which are cash profits that management can use to pay a dividend, repurchase its stock, or save on the balance sheet.

The stock is on sale

Remember I said that the stock rarely comes cheap? Investors should celebrate the occasional sale. Looking at valuation through the price-to-earnings ratio (P/E), Abbott Labs has commanded a median P/E of 31 over the past decade. The S&P 500’s historical average P/E is 15, so investors have been willing to pay a hefty premium to own shares.

Management is guiding non-GAAP (adjusted) EPS of $4.70 for 2022, pricing the stock at a P/E ratio of just under 22. Think of it as a sale where you can buy the stock at a 30% discount.

This isn’t the case every time; a stock that declines due to bad fundamentals, like slowing growth or a damaged balance sheet, can be a trap that investors occasionally fall into. However, Abbott’s continued growth and healthy profitability show that the stock’s decline is likely more opportunity than a mirage.

Justin Pope has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex Securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Act Fast - Promotion Ends In
Click Here To Get Started
Act Fast - Promotion Ends In
Click Here For More Info